Heart Disease Trial, Recruiting NCT06967194 Sponsor: Tel-Aviv Sourasky Medical Center Condition: Heart Disease
Back to Heart Disease

Heart Disease Trial, Recruiting

NCT06967194
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with a specific type of heart attack called an ST-segment elevation myocardial infarction (STEMI), confirmed by heart tracing (ECG), symptoms, and a heart artery procedure.
  • People who, after their heart artery procedure, are classified as a specific stage of heart instability (called "SCAI B") — meaning they have a fast heart rate and/or low blood pressure, but no signs that organs are being starved of blood (normal blood test results, normal circulation, clear thinking, and adequate urine output).
  • People aged 18 years or older.
  • People who are mentally able to understand and agree to take part, follow the study procedures, and follow medical guidance.

Who may not be able to join:

  • People who are pregnant.
  • People who are unable to give informed consent to participate.
  • People who show signs of fluid build-up in the lungs (pulmonary edema).
  • People with a slow heart rate (fewer than 60 beats per minute).
  • People with a specific abnormality on their heart tracing where the electrical signal between the upper and lower heart chambers is delayed beyond a certain threshold (PR interval greater than 240 milliseconds) (confirm with trial site).
  • People with certain types of heart rhythm problems where the electrical signals between the upper and lower chambers of the heart are partially or fully blocked (second- or third-degree AV block).
  • People with active asthma.
  • People who are known to have an allergic or adverse reaction to the medication metoprolol.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 13 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Yishay Szekely, MD, Tel-Aviv Sourasky Medical Center

Phone: 0544267898

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
21 May 2025
Est. completion
1 May 2027

Where this trial is recruiting

🇮🇱 Israel

Primary endpoints

Number of patients progressed from SCAI B to SCAI C

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov